The Continuous Glucose Monitoring Market size was valued at USD 7.92 Bn in 2023 and is expected to reach USD 11.10 Bn by 2031 and grow at a CAGR of 4.03% over the forecast period of 2024-2031.
The rise in the number of people suffering from diabetes all around the globe can be considered the major driving factor. According to the International Diabetes Federation (IDF) approx. 537 million are suffering from diabetes condition. The forecasted number according to the organization is 643 million by 2030. The major objective of our analysis is the factors that are contributing to this rise. The proportion of people suffering from diabetes is most probably high in developed countries. The reasons are obvious unhealthy lifestyles, overconsumption of alcohol, smoking, and so forth.
Get more information on Continuous Glucose Monitoring Market - Request Free Sample Report
Lately, World Health Organization (WHO) has confirmed, that non-communicable disease is considered the major reason for premature death. The rising technological advancement in the healthcare industry to prevent such diseases is on the elevated pitch. The advancement is itself the scope for the market to attract growth during the forecasted period.
The major problem with people suffering from diabetes is the sudden fluctuations of the body's glucose levels. This is where the opportunity for continuous glucose monitoring systems got introduced. The major role of the CGM is to keep continuous track of the body's glucose level. The CGM is a sensor that is been inserted under your skin mainly on the belly or arm. Along with the sensors, a monitor is been provided to track the glucose level, basically, the monitors are wireless. Some of the major features which make this component unique and fit into the marketplace are, it gives patients a warning in the form of an alarm when the glucose levels are high or when it’s too low. People suffering from Type 1 and Type 2 diabetes can use this system. The monitor that is provided can also help you to track your meals and record your past data to quantify your progress.
Driver
The rising number of people suffering from diabetes.
The unhealthy lifestyle is leading to the rise of people suffering from diabetes.
The rising demand for continuously tracking the body's glucose levels.
As we mentioned earlier the factor that is driving the market is the need for the continuous tracking of the body's glucose levels. The innovations of the tools and the components related to continuous glucose monitoring are on the rise. The rising sales of the companies that are innovating these components are increasing the value of the market in terms of sales volume and revenue. Abbott is the major player in this market which has assured the rise of the demand and the sales figure, which was somewhere around $4.8 Bn in 2022. If we consider the US market 11.3% of the people have diabetes which is creating a need for the CGM. These are the facts that are driving the market.
Restrain
The High cost associated with the CGM systems.
Opportunity
The rising awareness of CGM and the clinical trials for the same.
The rising technological advancement and the rising initiatives taken by the official government organizations to create awareness about diabetes conditions in undeveloped regions is a positive outlook for the market. According to clinicaltrials.gov/ there has been a rise in the clinical trials related to diabetes drug testing. The rising percentage of use of CGM in clinical trials is on the rise exceeding 5% to 12%. The approval by the Food Drug and Association (FDA) regarding the use of CGM and the support from the organizations in terms of tracking the problems faced by the users is indeed a positive element for the market. The rising number of users for CGM globally is a driving factor. For instance, Dexcom announced it achieved the number of 1.25 million users globally of CGM in 2021. The CAGR growth rate of the company was recorded at 41%.
Challenge
The uncertainty related to the accuracy of the glucose levels.
The strict laws and regulations related to data breaches and cyber threats limit the key players in terms of new innovation.
Impact of Recession
During a recession, people and families might experience financial difficulties, which would make healthcare supplies and services less affordable. The cost of the CGM system itself, the sensors, and ongoing maintenance might be high. Due to budgetary constraints, some people could decide to avoid, postpone, or use CGM systems.
Recessions can cause both an increase in the unemployment rate and a decline in the amount of health insurance coverage provided by employers. Individuals can find it difficult to afford CGM devices or incur higher out-of-pocket expenses if their insurance is canceled or their coverage is decreased. The affected individuals may adopt or use CGM less frequently as a result of this.
Economic effects: Both Russia's and Ukraine's economy have suffered as a result of the conflict. The industrial output of Ukraine has significantly decreased, its infrastructure has been harmed, and foreign investment has decreased. There has also been a disruption in trade between the two nations, which has an effect on businesses and livelihoods. Foreign investors have been discouraged by the violence, which has caused regional economic instability.
With thousands of deaths and millions of displaced people, the conflict has caused a serious humanitarian disaster. Infrastructure devastation, a lack of access to essentials, and a shortage of healthcare services have all hurt the civilian population. In addition, human rights violations and an increase in refugees and internally displaced people (IDPs) have been brought on by the war.
By Component
Sensors
Transmitters
Receivers
By End-Use Outlook
Hospitals
Home Care
Others
By Connectivity Outlook
Bluetooth
4G
Need any customization research on Continuous Glucose Monitoring Market - Enquiry Now
North America is the region with the highest market share in terms of users, revenue and so forth. There are several factors that contribute to the growth of this market in this region. The approvals of the drugs by the official government organizations related to the CGM. The major key players have stated that most of the revenue is been generated from the U.S. country. For instance, Abbott recorded $1 bn revenue from the US market only from its CGM Components and tools. Another factor is the unhealthy lifestyle of the people living in this region is terrifying, which is leading to a rise in chronic disease. Diabetes is one of them and that is the reason the North American region holds the largest potential of attracting growth during the forecasted period.
APAC is the region with the highest CAGR growth rate because of the rising clinical trials improvement in the healthcare infrastructure, and the rising economic condition of the major countries and individuals as well.
The major key players are Dexcom Inc, Medtronic Inc, Abbott Laboratories, Ypsomed AG, GlySens Incorporated, Ascensia Diabetes Care, F. Hoffmann-La Roche Ltd., and other players
Dexcom Inc – The official announcement by the company regarding the accessibility of the Dexcom G6 Real-Time CGM system to any eligible client managing diabetes with insulin through NIHB.
Abbott – The U.S. FDA has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring. Also, the company is working to get this system added to Medicare’s list of covered systems.
Medtronic – The approval from FDA for the MiniMed 780G System with the Guardian 4 Sensor.
| Report Attributes | Details |
| Market Size in 2023 | US$ 7.92 Bn |
| Market Size by 2031 | US$ 11.10 Bn |
| CAGR | CAGR of 4.03% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Component (Sensors, Transmitters, Receivers) • By End-Use Outlook (Hospitals, Home Care, Others) • By Connectivity Outlook (Bluetooth, 4G) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa]), Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Dexcom Inc, Medtronic Inc, Abbott laboratories, Ypsomed AG, GlySens Incorporated, Ascensia Diabetes Care, F. Hoffmann-La Roche Ltd. and others. |
| Key Drivers | • The rising number of people suffering from diabetes. • The unhealthy lifestyle which is leading to the rise of the people suffering from diabetes. • The rising demand for continuously tracking the body glucose levels. |
| Market Opportunities | • The rising awareness of the CGM and the clinical trials for the same. |
Ans : The Continuous Glucose Monitoring Market size was valued at USD 7.6 Bn in 2022.
Ans : The Continuous Glucose Monitoring Market is to grow at aa CAGR of 4.2% over the forecast period 2023-2030.
Ans : The uncertainty related to the accuracy of the glucose levels.
Ans; The U.S. FDA has cleared a reader for its FreeStyle Libre 3 integrated continuous glucose monitoring. Also, the company is working to get this system added to Medicare’s list of covered systems.
Ans : People suffering from Type 1 Type 2 diabetes can actually use this system
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of the Ukraine- Russia War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Continuous Glucose Monitoring Market Segmentation By Component
8.1 Sensors
8.2 Transmitters
8.3 Receivers
9. Continuous Glucose Monitoring Market By End-Use Outlook
9.1 Hospitals
9.2 Home Care
9.3 Others
10. Continuous Glucose Monitoring Market By Connectivity Outlook
10.1 Bluetooth
10.2 4G
11. Regional Analysis
11.1 Introduction
11.2 North America
11.2.1 North America Continuous Glucose Monitoring Diagnostics Market by country
11.2.2North America Continuous Glucose Monitoring Diagnostics Market by Component
11.2.3 North America Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.2.4 North America Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.2.5 USA
11.2.5.1 USA Continuous Glucose Monitoring Diagnostics Market by Component
11.2.5.2 USA Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.2.5.3 USA Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.2.6 Canada
11.2.6.1 Canada Continuous Glucose Monitoring Diagnostics Market by Component
11.2.6.2 Canada Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.2.6.3 Canada Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.2.7 Mexico
11.2.7.1 Mexico Continuous Glucose Monitoring Diagnostics Market by Component
11.2.7.2 Mexico Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.2.7.3 Mexico Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3 Europe
11.3.1 Eastern Europe
11.3.1.1 Eastern Europe Continuous Glucose Monitoring Diagnostics Market by country
11.3.1.2 Eastern Europe Continuous Glucose Monitoring Diagnostics Market by Component
11.3.1.3 Eastern Europe Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.1.4 Eastern Europe Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.1.5 Poland
11.3.1.5.1 Poland Continuous Glucose Monitoring Diagnostics Market by Component
11.3.1.5.2 Poland Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.1.5.3 Poland Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.1.6 Romania
11.3.1.6.1 Romania Continuous Glucose Monitoring Diagnostics Market by Component
11.3.1.6.2 Romania Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.1.6.4 Romania Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.1.7 Turkey
11.3.1.7.1 Turkey Continuous Glucose Monitoring Diagnostics Market by Component
11.3.1.7.2 Turkey Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.1.7.3 Turkey Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.1.8 Rest of Eastern Europe
11.3.1.8.1 Rest of Eastern Europe Continuous Glucose Monitoring Diagnostics Market by Component
11.3.1.8.2 Rest of Eastern Europe Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.1.8.3 Rest of Eastern Europe Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2 Western Europe
11.3.2.1 Western Europe Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.2 Western Europe Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.3 Western Europe Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.4 Germany
11.3.2.4.1 Germany Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.4.2 Germany Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.4.3 Germany Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.5 France
11.3.2.5.1 France Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.5.2 France Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.5.3 France Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.6 UK
11.3.2.6.1 UK Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.6.2 UK Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.6.3 UK Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.7 Italy
11.3.2.7.1 Italy Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.7.2 Italy Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.7.3 Italy Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.8 Spain
11.3.2.8.1 Spain Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.8.2 Spain Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.8.3 Spain Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.9 Netherlands
11.3.2.9.1 Netherlands Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.9.2 Netherlands Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.9.3 Netherlands Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.10 Switzerland
11.3.2.10.1 Switzerland Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.10.2 Switzerland Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.10.3 Switzerland Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.11.1 Austria
11.3.2.11.2 Austria Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.11.3 Austria Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.11.4 Austria Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.3.2.12 Rest of Western Europe
11.3.2.12.1 Rest of Western Europe Continuous Glucose Monitoring Diagnostics Market by Component
11.3.2.12.2 Rest of Western Europe Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.3.2.12.3 Rest of Western Europe Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4 Asia-Pacific
11.4.1 Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by country
11.4.2 Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by Component
11.4.3 Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.4 Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.5 China
11.4.5.1 China Continuous Glucose Monitoring Diagnostics Market by Component
11.4.5.2 China Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.5.3 China Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.6 India
11.4.6.1 India Continuous Glucose Monitoring Diagnostics Market by Component
11.4.6.2 India Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.6.3 India Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.7 Japan
11.4.7.1 Japan Continuous Glucose Monitoring Diagnostics Market by Component
11.4.7.2 Japan Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.7.3 Japan Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.8 South Korea
11.4.8.1 South Korea Continuous Glucose Monitoring Diagnostics Market by Component
11.4.8.2 South Korea Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.8.3 South Korea Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.9 Vietnam
11.4.9.1 Vietnam Continuous Glucose Monitoring Diagnostics Market by Component
11.4.9.2 Vietnam Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.9.3 Vietnam Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.10 Singapore
11.4.10.1 Singapore Continuous Glucose Monitoring Diagnostics Market by Component
11.4.10.2 Singapore Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.10.3 Singapore Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.11 Australia
11.4.11.1 Australia Continuous Glucose Monitoring Diagnostics Market by Component
11.4.11.2 Australia Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.11.3 Australia Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.4.12 Rest of Asia-Pacific
11.4.12.1 Rest of Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by Component
11.4.12.2 Rest of Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.4.12.3 Rest of Asia-Pacific Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5 Middle East & Africa
11.5.1 Middle East
11.5.1.1 Middle East Continuous Glucose Monitoring Diagnostics Market by country
11.5.1.2 Middle East Continuous Glucose Monitoring Diagnostics Market by Component
11.5.1.3 Middle East Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.1.4 Middle East Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.1.5 UAE
11.5.1.5.1 UAE Continuous Glucose Monitoring Diagnostics Market by Component
11.5.1.5.2 UAE Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.1.5.3 UAE Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.1.6 Egypt
11.5.1.6.1 Egypt Continuous Glucose Monitoring Diagnostics Market by Component
11.5.1.6.2 Egypt Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.1.6.3 Egypt Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.1.7 Saudi Arabia
11.5.1.7.1 Saudi Arabia Continuous Glucose Monitoring Diagnostics Market by Component
11.5.1.7.2 Saudi Arabia Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.1.7.3 Saudi Arabia Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.1.8 Qatar
11.5.1.8.1 Qatar Continuous Glucose Monitoring Diagnostics Market by Component
11.5.1.8.2 Qatar Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.1.8.3 Qatar Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.1.9 Rest of Middle East
11.5.1.9.1 Rest of Middle East Continuous Glucose Monitoring Diagnostics Market by Component
11.5.1.9.2 Rest of Middle East Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.1.9.3 Rest of Middle East Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.2 Africa
11.5.2.1 Africa Transfusion Diagnostics Market by country
11.5.2.2 Africa Continuous Glucose Monitoring Diagnostics Market by Component
11.5.2.3 Africa Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.2.4 Africa Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.2.5 Nigeria
11.5.2.5.1 Nigeria Continuous Glucose Monitoring Diagnostics Market by Component
11.5.2.5.2 Nigeria Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.2.5.3 Nigeria Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.2.6 South Africa
11.5.2.6.1 South Africa Continuous Glucose Monitoring Diagnostics Market by Component
11.5.2.6.2 South Africa Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.2.6.3 South Africa Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.5.2.7 Rest of Africa
11.5.2.7.1 Rest of Africa Continuous Glucose Monitoring Diagnostics Market by Component
11.5.2.7.2 Rest of Africa Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.5.2.7.3 Rest of Africa Continuous Glucose Monitoring Diagnostics Market by Connectivity Outlook
11.6 Latin America
11.6.1 Latin America Continuous Glucose Monitoring Diagnostics Market by country
11.6.2 Latin America Continuous Glucose Monitoring Diagnostics Market by Component Type
11.6.3 Latin America Continuous Glucose Monitoring Diagnostics Market by End-Use Outlook
11.6.4 Latin America Continuous Glucose Monitoring Diagnostics Market by End User
11.6.5 Brazil
11.6.5.1 Brazil America Continuous Glucose Monitoring Diagnostics by Component Type
11.6.5.2 Brazil America Continuous Glucose Monitoring Diagnostics by End-Use Outlook
11.6.5.3 Brazil America Continuous Glucose Monitoring Diagnostics by End User
11.6.6 Argentina
11.6.6.1 Argentina America Continuous Glucose Monitoring Diagnostics by Component Type
11.6.6.2 Argentina America Continuous Glucose Monitoring Diagnostics by End-Use Outlook
11.6.6.3 Argentina America Continuous Glucose Monitoring Diagnostics by End User
11.6.7 Colombia
11.6.7.1 Colombia America Continuous Glucose Monitoring Diagnostics by Component Type
11.6.7.2 Colombia America Continuous Glucose Monitoring Diagnostics by End-Use Outlook
11.6.7.3 Colombia America Continuous Glucose Monitoring Diagnostics by End User
11.6.8 Rest of Latin America
11.6.8.1 Rest of Latin America Continuous Glucose Monitoring Diagnostics by Component Type
11.6.8.2 Rest of Latin America Continuous Glucose Monitoring Diagnostics by End-Use Outlook
11.6.8.3 Rest of Latin America Continuous Glucose Monitoring Diagnostics by End User
12 Company profile
12.1 Dexcom Inc
12.1.1 Market Overview
12.1.2 Financials
12.1.3 Treatment/End-User/Offerings
12.1.4 SWOT Analysis
12.1.5 The SNS View
12.2 Medtronic Inc.
12.2.1 Market Overview
12.2.2 Financials
12.2.3 Treatment/End-User/Offerings
12.2.4 SWOT Analysis
12.2.5 The SNS View
12.3 Abbott laboratories.
12.3.1 Market Overview
12.3.2 Financials
12.3.3 Treatment/End-User/Offerings
12.3.4 SWOT Analysis
12.3.5 The SNS View
12.4 Ypsomed AG.
12.4.1 Market Overview
12.4.2 Financials
12.4.3 Treatment/End-User/Offerings
12.4.4 SWOT Analysis
12.4.5 The SNS View
12.5 GlySens Incorporated
12.5.1 Market Overview
12.5.2 Financials
12.5.3 Treatment/End-User/Offerings
12.5.4 SWOT Analysis
12.5.5 The SNS View
12.6 Ascensia Diabetes Care, and others.
12.6.1 Market Overview
12.6.2 Financials
12.6.3 Treatment/End-User/Offerings
12.6.4 SWOT Analysis
12.6.5 The SNS View
12.7 F. Hoffmann-La Roche Ltd.
12.7.1 Market Overview
12.7.2 Financials
12.7.3 Treatment/End-User/Offerings
12.7.4 SWOT Analysis
12.7.5 The SNS View
12.8 Others
12.8.2 Financials
12.8.3 Treatment/End-User/Offerings
12.8.4 SWOT Analysis
12.8.5 The SNS View
13. Competitive Landscape
13.1 Competitive Benchmarking
13.2 Market Share analysis
13.3 Recent Developments
14. Use Case and Best Practices
15. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Women’s Health Therapeutics Market size was valued at USD 13.8 billion in 2022 and is expected to reach USD 46.18 billion by 2030 and grow at a CAGR of 16.3% over the forecast period of 2023-2030.
In 2023, The Diabetic Ulcer Treatment Market size amounted to USD 10.31 Billion & is estimated to reach USD 15.59 Billion by 2031 and increase at a compound annual growth rate of 5.3% between 2024 and 2031.
The Blood Grouping Reagents Market Size was valued at USD 1.90 billion in 2022, and is expected to reach USD 4.11 billion by 2030 and grow at a CAGR of 10.1% over the forecast period 2023-2030.
The Near-infrared Imaging Market size was estimated USD 2.0 billion in 2022 and is expected to reach USD 2.6 billion by 2030 at a CAGR of 3.8% during the forecast period of 2023-2030.
The HIV Drugs Market size is expected to reach USD 43.06 Bn by 2031 and was valued at USD 32.7 Bn in 2023, the CAGR growth rate for HIV drug market is expected 3.5% over the forecast period of 2024-2031.
Spirometer Market size is valued at USD 1.12 Bn in 2023 and is expected to reach USD 2.39 Bn by 2031 and grow at a CAGR of 10.17% over the forecast period of 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
